Who are Century Therapeutics, Inc.'s main suppliers?

Century Therapeutics, Inc. (IPSC) key suppliers include: FCDI, FUJIFILM-CELLULAR-DYNAMICS-INC, Artiva Biotherapeutics, Inc., Celularity Inc., Fate Therapeutics, Inc. and 2 more. View the full supplier network at chainsifter.com/chain/IPSC.

Who are Century Therapeutics, Inc.'s major customers?

Century Therapeutics, Inc. (IPSC) key customers include: Bristol-Myers Squibb Company, Bristol-Myers Squibb Company, FCDI, Bristol-Myers Squibb Co, Bristol-Myers Squibb Co and 7 more. View the full customer network at chainsifter.com/chain/IPSC.

What sector is Century Therapeutics, Inc. in?

Century Therapeutics, Inc. (IPSC) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Century Therapeutics, Inc. Supplier List (IPSC): 7 Verified Suppliers

7Suppliers

12Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Century Therapeutics, Inc. (IPSC) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

23Total relationships

2Distinct source URLs

9High confidence

0.779Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Century Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
FCDI	FCDI	92%	On March 23, 2021, we entered into a Manufacturing and Supply Agreement with FCDI, or, as amended, the Manufacturing Agreement, pursuant to which FCDI will provide certain agreed upon technology tran…
FUJIFILM-CELLULAR-DYNAMICS-INC	FUJIFILM-CELLULAR-DYNAMICS-INC	92%	FCDI provides certain services to the Company to develop and manufacture iPSCs and immune cells derived therefrom
ARTV	Artiva Biotherapeutics, Inc.	72%	Reciprocal relationship from ARTV graph: uture environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or …
CELU	Celularity Inc.	72%	Reciprocal relationship from CELU graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from CELU graph: . Our pipeline reflects our intent to leverage the unique biology of the pla…
FATE	Fate Therapeutics, Inc.	72%	Reciprocal relationship from FATE graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from FATE graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from FATE g…
GDTC	CytoMed Therapeutics Limited	72%	Reciprocal relationship from GDTC graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from GDTC g…
INAB	IN8bio, Inc.	72%	Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not ye…

Century Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
BMY	Bristol-Myers Squibb Company	90%	the sublicenses under the FCDI Agreements pursuant to our former Research Collaboration and License Agreement with Bristol-Myers Squibb dated January 7, 2022, or the Collaboration Agreement
BMY	Bristol-Myers Squibb Company	90%	Reciprocal relationship from BMY graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from BMY graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from BMY grap…
FCDI	FCDI	90%	Pursuant to the Letter Agreement, and in consideration for amending the FCDI Agreements, we paid to FCDI (i) an upfront payment of $10.0 million, and will pay (ii) a percentage of any milestone payme…
BMYMP	Bristol-Myers Squibb Co	72%	Reciprocal relationship from BMYMP graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from IPSC graph: milestone payments upon the achie…
BMYMP	Bristol-Myers Squibb Co	72%	milestone payments upon the achievement of certain development and regulatory milestones up to an aggregate of $16.2 million or $12.15 million depending on the product. We additionally agreed to pay …
FATE	Fate Therapeutics, Inc.	72%	Reciprocal relationship from FATE graph: th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adversely…
GDTC	CytoMed Therapeutics Limited	72%	Reciprocal relationship from GDTC graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from GDTC g…
INAB	IN8bio, Inc.	72%	Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not ye…
TCRX	TScan Therapeutics, Inc.	72%	Reciprocal relationship from TCRX graph: ding transposase enzyme, which is derived from sfR fall armyworm, to deliver our TCRs into the genome of T cells. Our transposon/transposase system effectivel…
COMPANY-LLC	COMPANY-LLC	62%	or iPSC-derived allogeneic, cell therapy platforms; ● advance CNTY-813 and CNTY-308 through IND-enabling studies, submit IND applications and, if cleared, initiate and conduct clinical trials; ● cont…
FUJIFILM-CELLULAR-DYNAMICS-INC	FUJIFILM-CELLULAR-DYNAMICS-INC	62%	hospital processes are just beginning to be familiar and comfortable with their use. As a result, the execution and speed of enrollment of clinical trials in these novel and competitive areas are dif…
RHEINCELL-THERAPEUTICS-GMBH	RHEINCELL-THERAPEUTICS-GMBH	62%	hospital processes are just beginning to be familiar and comfortable with their use. As a result, the execution and speed of enrollment of clinical trials in these novel and competitive areas are dif…

Century Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
IPSC-DEBT-10343	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2021-12-31.
IPSC-DEBT-10342	Warrants outstanding: 16112	90%	xbrl warrant detail from xbrl 2021-12-31.
IPSC-DEBT	Debt stack $3.7M	90%	Market cache reports total debt of $3.7M.

Century Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Century Therapeutics, Inc..

Century Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
IPSC-OWNER-RA-CAPITAL-MANAGEMENT-L-P	RA CAPITAL MANAGEMENT, L.P.	90%	13F overlay lists RA CAPITAL MANAGEMENT, L.P. as top holder; 75 tracked holders.

Century Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
CRSP	CRISPR Therapeutics AG	100.00	2
ARTV	Artiva Biotherapeutics, Inc.	100.00	1	['supplier']
CPMV	Mosaic ImmunoEngineering, Inc.	100.00	2
TLSA	Tiziana Life Sciences Ltd	100.00	2
ACET	Adicet Bio, Inc.	100.00	2
CRBU	Caribou Biosciences, Inc.	100.00	2
DTIL	Precision BioSciences, Inc.	100.00	2
AUTL	Autolus Therapeutics plc	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
CHRS	Coherus Oncology, Inc.	100.00	2
EDIT	Editas Medicine, Inc.	100.00	2
BEAM	Beam Therapeutics Inc.	100.00	2
REGN	Regeneron Pharmaceuticals, Inc.	100.00	2
ALLO	Allogene Therapeutics, Inc.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
ATRA	Atara Biotherapeutics, Inc.	100.00	2
EMMA	Emmaus Life Sciences, Inc.	100.00	2
FATE	Fate Therapeutics, Inc.	100.00	2	['customer', 'supplier']
SDGR	Schrödinger, Inc.	100.00	2
CLLS	Cellectis S.A.	100.00	2

Century Therapeutics, Inc. Supply Chain